Cluster page — medicines optimisation
Problematic polypharmacy
Definition
Appropriate vs problematic polypharmacy
Polypharmacy is not, in itself, a clinical problem. A patient with heart failure, atrial fibrillation, type 2 diabetes and chronic kidney disease may appropriately need 12+ regular medicines. The clinical question — and the focus of NHS England's Polypharmacy programme — is whether the regimen is appropriate for that individual patient, or whether the harm-to-benefit ratio has shifted and the regimen has become problematic.
Problematic polypharmacy is associated with falls, cognitive impairment, hospital admission, treatment burden and reduced quality of life. The over-75 cohort on 10+ regular medicines is the primary care population where these risks concentrate, and structured polypharmacy review — using STOPP/START, anticholinergic burden assessment and shared decision-making — is the evidence-based response.
Polypharmacy review tools
What the PCN pharmacist actually uses
- STOPP/START version 3 — potentially inappropriate / under-prescribed medicines in over-65s
- Anticholinergic Cognitive Burden (ACB) scale — cognition and falls risk
- Drug Burden Index — sedative and anticholinergic exposure quantification
- Beers Criteria (AGS) — adjunct list for cross-checking
- NHS England Polypharmacy: Getting our medicines right toolkit (7-step framework)
- PrescQIPP polypharmacy bulletins — therapy-area specific deprescribing prompts
Population numbers
Polypharmacy in a typical 50k PCN
Frequently asked questions
Polypharmacy — FAQs
What is 'problematic' polypharmacy?+
NHS England distinguishes appropriate polypharmacy (multiple medicines all clinically justified) from problematic polypharmacy (multiple medicines where the harm outweighs benefit for that patient, or where the regimen is unmanageable). The 10+ regular medicines threshold is the operational proxy, but the clinical judgement is on appropriateness, not count.
What tools identify polypharmacy risk?+
STOPP/START version 3 (potentially inappropriate prescribing in older adults), the Anticholinergic Cognitive Burden scale, the Drug Burden Index, and the Beers Criteria. NHS England's Polypharmacy: Getting our medicines right toolkit operationalises these for SMR delivery.
Why does polypharmacy matter at PCN scale?+
30–40% of over-75s in a typical PCN list are on 10+ regular medicines. This cohort accounts for the majority of medication-related hospital admissions, falls, and adverse drug reactions in primary care — and is the highest-yield deprescribing opportunity under the PCN DES.
How is polypharmacy work funded?+
Through the DES SMR cohort delivery (the 10+ medicines cohort is one of the named DES priority groups) and through ICB-commissioned deprescribing programmes that supplement the DES.
Talk to our Service Development team
30-minute discovery call. We'll show you how BCS maps to your PCN's specific priorities.